video corpo

Colorectal cancer assay kit Praxis Extended RAS
for genetic mutationsfor KRAS mutationsfor NRAS mutations

colorectal cancer assay kit
colorectal cancer assay kit
Add to favorites
Compare this product


colorectal cancer, for genetic mutations
Tested parameter
for KRAS mutations, for NRAS mutations
Sample type
for DNA


To evaluate mutations known to affect the efficacy of Vectibix* for treatment of metastatic colorectal cancer,1,2 Illumina offers the Praxis Extended RAS Panel. This Food and Drug Administration (FDA)-approved next-generation sequencing (NGS) kit assesses 12 codons in KRAS/NRAS to simultaneously determine the presence of 56 activating mutations. The Praxis Extended RAS Panel is used to aid in the identification of patients eligible for treatment with Vectibix. The panel is intended to be used on the MiSeqDx instrument. On-instrument Local Run Manager software helps create a sequencing run, monitor run status, and analyze the sequencing data. It then delivers an easy-to-interpret report to guide therapy decisions accurately and efficiently. First fully validated NGS-based companion diagnostic for Vectibix FDA-approved test to evaluate 56 KRAS/NRAS mutations in a single assay Integrated, streamlined workflow Comprehensive diagnostic solution, including library prep, sequencing, and clinical report Extended gene coverage Simultaneous detection of 56 RAS mutations contraindicated for Vectibix therapy3,4


No catalogs are available for this product.

See all of Illumina, Inc.‘s catalogs
*Prices are pre-tax. They exclude delivery charges and customs duties and do not include additional charges for installation or activation options. Prices are indicative only and may vary by country, with changes to the cost of raw materials and exchange rates.